Jubilant Ingrevia Ltd declared the issuance of commercial papers aggregating INR 1 billion, reflecting its prudent strategy to address short-term funding requirements. The step is a manifestation of the company's sound financial planning and concern for liquidity to ensure operational excellence. As a company renowned for its diversified life science portfolio, Jubilant Ingrevia remains inclined to utilize financial instruments in favor of its growth path.
The issuance is in line with the firm's healthy credit rating, reaffirmed as 'CRISIL A1+', reflecting its sound business risk profile and financial strength. Jubilant Ingrevia's vertically integrated business and diversified revenue base across geographies and industries have established it as a creditworthy player in the industry.
This move is in line with a string of strategic moves made by Jubilant Ingrevia, ranging from joint ventures to investments aimed at improving its manufacturing strengths and international reach. The issuance of commercial paper will also help shore up the firm's capability to withstand market oscillations while continuing its growth impetus.
Source: MT Newswires